Tatiana Golovina serves as the Senior Vice President of Development at BlueWhale Bio, where she plays a pivotal role in advancing the company’s innovative platform for next-generation cell and gene therapies. With over 20 years of experience in the biotechnology sector, Tatiana’s expertise spans a...
Tatiana Golovina serves as the Senior Vice President of Development at BlueWhale Bio, where she plays a pivotal role in advancing the company’s innovative platform for next-generation cell and gene therapies. With over 20 years of experience in the biotechnology sector, Tatiana’s expertise spans a comprehensive range of disciplines, including analytical development, translational research, and immunology. Her extensive background in T lymphocyte research and protein purification positions her uniquely to tackle the complex challenges associated with the manufacturing of cell therapies, particularly in enhancing efficacy, durability, and cost-effectiveness.
At BlueWhale Bio, Tatiana leads key projects that focus on the validation of targets and assays, ensuring that the therapeutic candidates meet rigorous regulatory standards. Her analytical acumen is complemented by hands-on experience in techniques such as Western blotting, PCR, and real-time polymerase chain reaction (qPCR), which are critical for the characterization and expression of therapeutic proteins. Tatiana’s leadership is instrumental in bridging the gap between bench research and clinical application, driving the development of robust processes that facilitate the transition from laboratory discoveries to viable treatments.
Her commitment to innovation in biotechnology not only enhances the company’s capabilities but also contributes to the broader field of cancer research. By fostering collaboration across multi-disciplinary teams, Tatiana ensures that BlueWhale Bio remains at the forefront of the rapidly evolving landscape of cell and gene therapies, ultimately aiming to improve patient outcomes and transform therapeutic modalities.
